Drug Trial Radar · NCT06971614
A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC
Last checked: Nov 19, 2026Latest source record: Aug 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Jun 9, 2025
Primary completion
Dec 31, 2028
Study completion May 31, 2029
Sponsor
- Lead sponsor
- ImmVira Pharma Co. LtdIndustry
- Sponsor type
- Industry
- First posted
- May 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase II clinical study to evaluate the efficacy and safety of intravesical T3011 injection in participants with BCG-unresponsive high-risk NMIBC or BCG-exposed, chemotherapy-unresponsive intermediate/high-risk NMIBC.
Conditions
- Nonmuscle-invasive Bladder Cancer
Interventions
T3011Biological
T3011 will be administered at a dose of 1x10\^10 PFU intravesically.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete Response Rate in patients with CISTime frame: 3,6,12 months time point from the date of the first dose of T3011
- Recurrence Free Survival Rate in patients with Ta/T1 (without CIS)Time frame: 3,6,12 months time point from the date of the first dose of T3011
- Incidence rates of Grade ≥3 treatment-related adverse events (TRAEs)Time frame: 24 months
- Incidence rates of TRAEs leading to treatment discontinuation, dose modification or treatment interruption.Time frame: 24 months
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
East Valley Urology Center
Queen Creek, Arizona · Recruiting
Tower Urology
Los Angeles, California · Recruiting
Advent Health Medical Group Urology
Orlando, Florida · Recruiting
Florida Urology Partners, LLP
Tampa, Florida · Recruiting
Rutgers Cancer Institute
New Brunswick, New Jersey · Recruiting
University of Cincinnati Medical Center
Cincinnati, Ohio · Recruiting
Helios Clinical Research
Middleburg Heights, Ohio · Recruiting
Allegheny Health Network
Pittsburgh, Pennsylvania · Recruiting
Carolina Urologic Research Center
Myrtle Beach, South Carolina · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.